Evidence map›Paper›PMID 38190096›Full record

ArticleTissue engineering and regenerative medicine2024

Efficacy of IFN-γ-Primed Umbilical Cord-Derived Mesenchymal Stem Cells on Temporomandibular Joint Osteoarthritis.

Hyunjeong Kim, Yerin Kim, So-Yeon Yun, Bu-Kyu Lee

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering and regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hyunjeong KimBiomedical Engineering Research Center, Asan Medical Center, Asan Institute for Life Sciences, Seoul, Korea.ORCID 0009-0008-5569-4923
Yerin KimAsan Medical Center, AMIST, College of Medicine, University of Ulsan, Seoul, Korea.ORCID 0009-0008-9721-9004
So-Yeon YunAsan Medical Center, AMIST, College of Medicine, University of Ulsan, Seoul, Korea.ORCID 0009-0009-9589-8733
Bu-Kyu LeeBiomedical Engineering Research Center, Asan Medical Center, Asan Institute for Life Sciences, Seoul, Korea. bukyu.lee@gmail.com.ORCID 0000-0001-8888-1719
Asan Medical Center · KR

Funding

Korea Health Industry Development Institute H21C0168
6 · The paper itself

Abstract

backgroundTemporomandibular joint osteoarthritis (TMJOA) is a degenerative disease affecting the cartilage and subchondral bone, leading to temporomandibular joint pain and dysfunction. The complex nature of TMJOA warrants effective alternative treatments, and mesenchymal stem cells (MSCs) have shown promise in regenerative therapies. The aim of this study is twofold: firstly, to ascertain the optimal interferon-gamma (IFN-γ)-primed MSC cell line for TMJOA treatment, and secondly, to comprehensively evaluate the therapeutic efficacy of IFN-γ-primed mesenchymal stem cells derived from the human umbilical cord matrix in a rat model of TMJOA.

methodsWe analyzed changes in the expression of several key genes associated with OA protection in MSC-secreted compounds. Following this, we performed co-culture experiments using a transwell system to predict gene expression changes in primed MSCs in the TMJOA environment. Subsequently, we investigated the efficacy of the selected IFN-γ-primed human umbilical cord matrix-derived MSCs (hUCM-MSCs) for TMJOA treatment in a rat model.

resultsIFN-γ-primed MSCs exhibited enhanced expression of IDO, TSG-6, and FGF-2. Moreover, co-culturing with rat OA chondrocytes induced a decrease in pro-inflammatory and extracellular matrix degradation factors. In the rat TMJOA model, IFN-γ-primed MSCs with elevated IDO1, TSG-6, and FGF2 expression exhibited robust anti-inflammatory and therapeutic capacities, promoting the improvement of the inflammatory environment and cartilage regeneration.

conclusionThese findings underscore the importance of prioritizing the mitigation of the inflammatory milieu in TMJOA treatment and highlight IFN-γ-primed MSCs secreting these three factors as a promising, comprehensive therapeutic strategy.

Indexed as

Mesenchymal Stem CellsOsteoarthritisAnimalsHumansInterferon-gammaRatsTemporomandibular JointUmbilical CordInterferon-gammaAnti-inflammatoryHuman umbilical cord matrix-derived MSCIFN-γ-primed MSCsTemporomandibular joint osteoarthritisTherapeutic potential

Identifiers

PMID38190096
PMCPMC10987468
OpenAlexW4390672836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.